Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
Adobe
By Elaine Chen
June 7, 2026
National Biotech Reporter
Elaine Chen
A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out…
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on…
At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other…
Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could…
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how…
The highest dose of Eli Lilly's weekly injection helped patients with obesity or who are overweight lose 20.1% of their body…
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
Nearly 1 in 5 patients quit Boehringer and Zealand’s obesity shot over side effects
With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race
US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market
Pfizer's good-enough obesity data in a crowded market may force competition on price, dosing
Weight loss drug maker sinks 25% after new safety data spooks investors
ADA: Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes
AstraZeneca's obesity pill matches rivals in Phase 2, anchoring $5B franchise push
